This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-26. Anything still debated is marked as such rather than presented as settled.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Generation Z's top career choices—becoming business people, doctors, engineers, artists, and IT workers—are not that different from generations past. For them, the most important qualities in a job are income, fulfillment, work-life balance, and job security. In particular, Generation Z prioritizes a work-life balance more than older cohorts and are highly interested in flexible work schedules. Millennials and Generation Z (74%) tend to have more colleagues working remotely for a significant portion of their time compared to the Baby Boomers (58%). Most members of Generation Z prefer to work for a medium or large company rather than a startup or a government agency. Access to the Internet has made self-employment much easier than it was in the past; indeed, by the mid-2010s, a majority of Generation Z were running their own businesses instead of holding "traditional" teen jobs, such as waiting tables. Morgan Stanley reported in 2019 that Millennials and Generation Z have been responsible for a surge in labor participation in the United States, and that while the American workforce was expanding, other G10 countries faced a shrinking number of workers. This development alleviates concerns over America's aging population which jeopardizes the solvency of various welfare programs. As of 2019, Millennials and Generation Z accounted for 38% of the American workforce, a number that is projected to rise to 58% in the incoming decade.
The endothelial cells retract and the leukocytes pass through the basement membrane into the surrounding tissue using adhesion molecules such as ICAM-1. Movement of leukocytes within the tissue via chemotaxis: Leukocytes reaching the tissue interstitium bind to extracellular matrix proteins via expressed integrins and CD44 to prevent them from leaving the site. A variety of molecules behave as chemoattractants, for example, C3a or C5a (the anaphylatoxins), and cause the leukocytes to move along a chemotactic gradient towards the source of inflammation.
Brenner's work includes the first human trial of NR, which demonstrated safe oral availability as an NAD+ precursor. His work characterized ways in which the NAD system is disrupted by diseases and conditions of metabolic stress. Further, he identified a specific mechanism by which citrin deficiency results in sweet aversion and metabolic dysfunction-associated steatotic liver disease (MASLD), and identified glycerol-3-phosphate as the activator of carbohydrate response element binding protein (ChREBP).
=== Protein tags === BCCP (Biotin Carboxyl Carrier Protein), a protein domain biotinylated by BirA enabling recognition by streptavidin BromoTag, a "bump-and-hole" mutated version of the second bromodomain of Brd4, Brd4-BD2 L387A, that can be highly selectively bound by tag-specific PROTAC degrader AGB1 to form a ternary complex between the "BromoTagged" protein and the E3 ligase VHL, leading to ubiquitination of the tagged protein and its subsequent rapid and effective proteasomal degradation in cells. FAST (Fluorescence-Activating and absorption-Shifting Tag), a mutated photoactive yellow protein (PYP) that reversibly binds cognate fluorogenic ligands CL7-tag, an engineered variant of Colicin E7 that has a strong binding affinity and specificity for immobilized Immunity Protein 7 (Im7). Glutathione-S-transferase-tag, a protein which binds to immobilized glutathione Green fluorescent protein-tag, a protein which is spontaneously fluorescent and can be bound by nanobodies HaloTag, a mutated bacterial haloalkane dehalogenase that covalently attaches to haloalkane substrates SNAP-tag, a mutated eukaryotic DNA methyltransferase that covalently attaches to benzylguanine derivatives CLIP-tag, a mutated eukaryotic DNA methyltransferase that covalently attaches to benzylcytosine derivatives HUH-tag, a sequence-specific single-stranded DNA binding protein that covalently binds to its target sequence Maltose binding protein-tag, a protein which binds to amylose agarose Nus-tag Thioredoxin-tag Fc-tag, derived from immunoglobulin Fc domain, allow dimerization and solubilization.
Computational chemistry is simplest in gas-phase chemistry, in which interactions between molecules may be ignored as negligible. Multiple authors have researched dubnium pentachloride; calculations show it to be consistent with the periodic laws by exhibiting the properties of a compound of a group 5 element. For example, the molecular orbital levels indicate that dubnium uses three 6d electron levels as expected. Compared to its tantalum analog, dubnium pentachloride is expected to show increased covalent character: a decrease in the effective charge on an atom and an increase in the overlap population (between orbitals of dubnium and chlorine). Calculations of solution chemistry indicate that the maximum oxidation state of dubnium, +5, will be more stable than those of niobium and tantalum and the +3 and +4 states will be less stable. The tendency towards hydrolysis of cations with the highest oxidation state should continue to decrease within group 5 but is still expected to be quite rapid. Complexation of dubnium is expected to follow group 5 trends in its richness. Calculations for hydroxo-chlorido- complexes have shown a reversal in the trends of complex formation and extraction of group 5 elements, with dubnium being more prone to do so than tantalum.
Sources: en.wikipedia.org
=== In prokaryotes === In prokaryotes a small 30S ribosomal subunit contains the 16S ribosomal RNA. The large 50S ribosomal subunit contains two rRNA species (the 5S and 23S ribosomal RNAs). Therefore it can be deduced that in both bacteria and archaea there is one rRNA gene that codes for all three rRNA types :16S, 23S and 5S. Bacterial 16S ribosomal RNA, 23S ribosomal RNA, and 5S rRNA genes are typically organized as a co-transcribed operon. As shown by the image in this section, there is an internal transcribed spacer between 16S and 23S rRNA genes. There may be one or more copies of the operon dispersed in the genome (for example, Escherichia coli has seven). Typically in bacteria there are between one and fifteen copies. Archaea contains either a single rRNA gene operon or up to four copies of the same operon. The 3' end of the 16S ribosomal RNA (in a ribosome) recognizes a sequence on the 5' end of mRNA called the Shine-Dalgarno sequence.
== History == The effect of grapefruit juice on drug absorption was discovered in 1989 by a group led by pharmacologist David Bailey. Their first published clinical report on grapefruit vs. drug interactions was in 1991. The effect was discovered accidentally in 1989, when a test of drug interactions with alcohol used grapefruit juice to hide the taste of the ethanol. A 2005 medical review advised patients to avoid all citrus juices until further research clarified the risks. It was reported in 2008 that similar effects had been observed with apple juice.
The primary structure of a protein refers to the sequence of amino acids in the polypeptide chain. The primary structure is held together by peptide bonds that are made during the process of protein biosynthesis. The two ends of the polypeptide chain are referred to as the carboxyl terminus (C-terminus) and the amino terminus (N-terminus) based on the nature of the free group on each extremity. Counting of residues always starts at the N-terminal end (NH2-group), which is the end where the amino group is not involved in a peptide bond. The primary structure of a protein is determined by the gene corresponding to the protein. A specific sequence of nucleotides in DNA is transcribed into mRNA, which is read by the ribosome in a process called translation. The sequence of amino acids in insulin was discovered by Frederick Sanger, establishing that proteins have defining amino acid sequences. The sequence of a protein is unique to that protein, and defines the structure and function of the protein. The sequence of a protein can be determined by methods such as Edman degradation or tandem mass spectrometry. Often, however, it is read directly from the sequence of the gene using the genetic code. It is strictly recommended to use the words "amino acid residues" when discussing proteins because when a peptide bond is formed, a water molecule is lost, and therefore proteins are made up of amino acid residues. Post-translational modifications such as phosphorylations and glycosylations are usually also considered a part of the primary structure, and cannot be read from the gene.
=== Therapeutic foods === Due in part to limited research on supplementary feeding, there is little evidence that this strategy is beneficial. A 2015 systematic review of 32 studies found that there are limited benefits when children under 5 receive supplementary feeding, especially among younger, poorer, and more undernourished children. However, specially formulated foods do appear to be useful in treating moderate acute malnutrition in the developing world. These foods may have additional benefits in humanitarian emergencies, since they can be stored for years, can be eaten directly from the packet, and do not have to be mixed with clean water or refrigerated. In young children with severe acute malnutrition, it is unclear if ready-to-use therapeutic food differs from a normal diet. Severely malnourished individuals can experience refeeding syndrome if fed too quickly. Refeeding syndrome can result regardless of whether food is taken orally, enterally or parenterally. It can present several days after eating with potentially fatal heart failure, dysrhythmias, and confusion. Some manufacturers have fortified everyday foods with micronutrients before selling them to consumers. For example, flour has been fortified with iron, zinc, folic acid, and other B vitamins like thiamine, riboflavin, niacin and vitamin B12. Baladi bread (Egyptian flatbread) is made with fortified wheat flour. Other fortified products include fish sauce in Vietnam and iodized salt.
Sources: en.wikipedia.org
=== Medication === For type B aortic dissections, patients without rupture of the aorta or organ perfusion abnormalities may be treated with medications. For others, including those with type A aortic dissections, surgery is preferred. Aortic dissection generally presents as a hypertensive emergency, and the main consideration of medical management is to decrease the shear stress in the aortic wall by decreasing blood pressure and the heart rate. The target blood pressure should be a mean arterial pressure (MAP) of 60 to 75 mmHg or a systolic blood pressure between 100-120 mmHg, or the lowest blood pressure tolerated. Initial decreases should be by about 20%. The target heart rate is 60-80 beats per minute. Long-term blood pressure control is required for every person who has experienced aortic dissection. Beta blockers are the first-line treatment for patients with acute and chronic aortic dissection. In acute dissection, fast-acting agents can be given intravenously and have doses that are easier to adjust (such as esmolol, propranolol, or labetalol) is preferred. Vasodilators such as sodium nitroprusside can be considered for people with ongoing high blood pressure, but they should never be used alone, as they often stimulate a reflexive increase in the heart rate. Opiates are commonly used for relief of severe pain and may lower the blood pressure further. Calcium channel blockers can be used in the treatment of aortic dissection, particularly if a contraindication to the use of beta-blockers exists.
These time and length-scales can be used to understand the dependence of the conduction velocity on the diameter of the neuron in unmyelinated fibers. For example, the time-scale τ increases with both the membrane resistance rm and capacitance cm. As the capacitance increases, more charge must be transferred to produce a given transmembrane voltage (by the equation Q = CV); as the resistance increases, less charge is transferred per unit time, making the equilibration slower. In a similar manner, if the internal resistance per unit length ri is lower in one axon than in another (e.g., because the radius of the former is larger), the spatial decay length λ becomes longer and the conduction velocity of an action potential should increase. If the transmembrane resistance rm is increased, that lowers the average "leakage" current across the membrane, likewise causing λ to become longer, increasing the conduction velocity.
Seydina Oumar Sy - Minister of Foreign Affairs Thierno Alassane Sall - Former Minister of Energy, Infrastructure, Land Transport, Senegal. Fatma Samoura - Diplomat, First Female secretary General of FIFA. Aïssata Tall Sall- Minister of Foreign Affairs; Senegal Zahra Iyane Thiam - Former Minister of Microfinance and Social and Solidarity Economy, Senegal. Abdoulkader Thiam Abdallahi Mahmoud Abdoulaye Ba Adama Ba Ahmed Sidibé - Mauritanian Football Manager and former player Aly Abeid— Football player; Mauritania Houssen Abderrahmane Bilal Sidibé - Mauritanian football player Ibrahim Ba Issa Ba Issiar Dia Mohamed Dellahi Yali Moussa Sow- Football player Pape Habib Sow Aïssata Tall Sall - Minister of Foreign Affairs, Senegal Abdou Diallo - Senegalese professional footballer who plays for RB Leipzig. Kalidou Koulibaly - Senegalese professional footballer who plays for Al Hilal SFC. Bambo Diaby El Hadji Ba Lamine Ba Demba Ba El Mami Tetah Papa Malick Ba Mohamed Saqr Mouhamadou Dabo Mamadou Fall Idrissa Thiam Djeidi Gassama Ousseynou Ba
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.